Here are 1-3 brief analogies to describe Pelthos Therapeutics:

1. Imagine a very early-stage Vertex Pharmaceuticals, but focused on developing non-addictive pain treatments for genetically validated conditions like Erythromelalgia.

2. A specialized pain management biotech aiming to offer non-addictive opioid alternatives, much like BioMarin Pharmaceutical develops therapies for rare genetic diseases.

3. They're pioneering a new class of non-addictive pain medication with a safer, targeted approach, similar to how Moderna developed novel mRNA vaccine technology.

• CC8464 (for Erythromelalgia): A clinical-stage therapeutic designed to selectively block NaV1.7 sodium channels in the peripheral nervous system for the treatment of Erythromelalgia.
• CC8464 (Ophthalmic Formulation for Eye Pain): A clinical-stage topical formulation of CC8464 being developed to alleviate eye pain by targeting NaV1.7 receptors on the cornea.
• Diclofenac Spray Formulation: A licensed therapeutic product.
• Rizatriptan Spray Formulation: A licensed therapeutic product.
• Ondansetron Spray Formulation: A licensed therapeutic product.

• Patients: Individuals suffering from Erythromelalgia (EM), and potentially other pain conditions, who would receive the prescription.
• Healthcare Providers/Physicians: The medical professionals who diagnose EM and prescribe appropriate treatments.

Scott M. Plesha, Chief Executive Officer

Mr. Plesha joined Pelthos in November 2023 and has over 30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial organizations. Prior to Pelthos, he served as President and Chief Commercial Officer at BioDelivery Sciences (BDSI) until its acquisition by Collegium Pharmaceutical in 2022, where he led BDSI sales growth from $5 million to $160 million. He also held the position of Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals.

Frank Knuettel II, Chief Financial Officer

Mr. Knuettel joined Pelthos as CFO in July 2025, following his leadership in the merger with Pelthos Therapeutics. He has spent most of his career as a CFO in early-stage public companies, specializing in dynamic technology and life sciences. Before the merger, he served as Chief Executive Officer of Channel Therapeutics Corporation from July 2023 and its Chief Financial Officer from June 2022.

Sai Rangarao, Chief Commercial Officer

Mr. Rangarao serves as Chief Commercial Officer at Pelthos, joining the company in March 2024. He brings over a decade of experience in leading, launching, and marketing large and highly differentiated pharmaceutical products. Previously, Mr. Rangarao was the Vice President of Marketing at Collegium Pharmaceutical.

Key Risks to the Business

1. Pelthos Therapeutics' business is highly dependent on the successful clinical development, regulatory approval, and commercialization of its single lead compound, CC8464. Any failure in the ongoing or planned clinical trials for CC8464, whether due to safety concerns (such as the previously observed rashes necessitating a modified dose escalation strategy), lack of efficacy, or unfavorable regulatory feedback, would severely impact the company's prospects. Additionally, a prior development agreement for CC8464 with Astellas Pharma Inc. was terminated in 2018, leading to the return of all rights to Pelthos' predecessor.

2. The primary target indication for CC8464, Erythromelalgia (EM), is a rare condition with a limited patient population, estimated between 5,000 to 50,000 persons in the U.S. This restricted market size may limit the potential peak sales and overall commercial viability of CC8464, even if it achieves regulatory approval.

3. Pelthos' efforts to diversify its pipeline beyond systemic CC8464 for EM are in very early stages. The development of a topical ophthalmic formulation of CC8464 for eye pain has only recently commenced with initial toxicology and in vivo studies planned, followed by a proof-of-concept trial. All other internally discovered compounds are currently pre-clinical, indicating a long and uncertain path to clinical development and potential commercialization.

The following clear emerging threats have been identified for Pelthos Therapeutics:

• Prior Termination of Agreement by Astellas Pharma Inc.: In 2018, Astellas Pharma Inc. terminated its joint development and commercialization agreement for CC8464, returning all rights to Chromocell Holdings (Pelthos's predecessor). While the specific reasons for this termination are not disclosed, the fact that a major pharmaceutical partner chose to abandon the compound after engaging in joint development suggests significant, undisclosed concerns regarding CC8464's clinical profile, safety, or commercial potential. As Pelthos now proceeds with the development of CC8464, these underlying issues could re-emerge and pose a substantial threat to the compound's ultimate success and market viability.
• Safety/Tolerability Issues with Rashes in Phase 1 Trial: During the Phase 1 trial for CC8464, certain incidents of rashes were observed. While Pelthos has developed a mitigation strategy involving slower dose escalation, hospitalization, and frequent physical examinations, the need for such extensive measures highlights a potentially significant safety and tolerability challenge. If the slower dose escalation trial, expected to launch in early 2024, fails to adequately mitigate these skin reactions, or if the burden of managing these side effects (e.g., hospitalization, frequent exams) is deemed too high for a chronic pain treatment, it could severely limit CC8464's approval and commercial adoption. The success or failure of this mitigation strategy in the upcoming trials represents an emerging threat to the drug's future.

Pelthos Therapeutics (PTHS) has several expected drivers of future revenue growth over the next 2-3 years, primarily stemming from its clinical pipeline and strategic licensing efforts:

1. Advancement of CC8464 for Erythromelalgia (EM) through clinical trials: Pelthos's lead compound, CC8464, is undergoing a dose escalation study with patient procurement expected in early 2024 and first patient dosing in the third quarter of 2024, anticipated to take approximately nine months. Subsequently, a Phase 2a proof-of-concept study for efficacy in genetically validated EM patients is expected to launch in the second half of 2025 and take approximately twelve months. Successful progression through these clinical stages could significantly increase the asset's value, potentially leading to lucrative partnership agreements, including upfront payments and milestone revenues, as the compound moves closer to potential approval and commercialization.
2. Development and potential commercialization of CC8464 as a topical agent for eye pain: Pelthos intends to explore the viability of developing CC8464 as a topical agent for the relief of eye pain, noting that topical administration is unlikely to lead to systemic side effects seen with systemic administration. The company has commenced development of a topical ophthalmic formulation of CC8464, with trials expected to start in the third quarter of 2024. This represents an expansion into a new indication with a potentially different and possibly faster regulatory pathway, which could lead to earlier market entry or partnership opportunities, generating revenue through milestones or direct sales.
3. Revenue generation from in-licensed Diclofenac, Rizatriptan, and Ondansetron Spray Formulations: Pelthos has disclosed the licensing of Diclofenac Spray Formulation, Rizatriptan Spray Formulation, and Ondansetron Spray Formulation. While specific timelines for their commercialization or current revenue contribution are not detailed in the background, these in-licensed assets represent additional pipeline components. Any progress towards their commercialization, increased market penetration, or royalty streams from these products would directly contribute to Pelthos's revenue growth within the forecast period.